- Home
- ONL vs FULC Comparison
ONL vs FULC Comparison
Compare ONL & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONL
- FULC
- Stock Information
- Founded
- ONL 2021
- FULC 2015
- Country
- ONL United States
- FULC United States
- Employees
- ONL N/A
- FULC N/A
- Industry
- ONL Real Estate Investment Trusts
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- ONL Real Estate
- FULC Health Care
- Exchange
- ONL Nasdaq
- FULC Nasdaq
- Market Cap
- ONL 226.6M
- FULC 221.5M
- IPO Year
- ONL N/A
- FULC 2019
- Fundamental
- Price
- ONL $4.01
- FULC $2.97
- Analyst Decision
- ONL Hold
- FULC Hold
- Analyst Count
- ONL 1
- FULC 10
- Target Price
- ONL N/A
- FULC $7.44
- AVG Volume (30 Days)
- ONL 252.5K
- FULC 816.2K
- Earning Date
- ONL 11-07-2024
- FULC 11-13-2024
- Dividend Yield
- ONL 9.97%
- FULC N/A
- EPS Growth
- ONL N/A
- FULC N/A
- EPS
- ONL N/A
- FULC N/A
- Revenue
- ONL $169,644,000.00
- FULC $80,871,000.00
- Revenue This Year
- ONL N/A
- FULC $2,821.96
- Revenue Next Year
- ONL N/A
- FULC N/A
- P/E Ratio
- ONL N/A
- FULC N/A
- Revenue Growth
- ONL N/A
- FULC 2987.86
- 52 Week Low
- ONL $3.01
- FULC $2.86
- 52 Week High
- ONL $6.22
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- ONL 54.63
- FULC 32.31
- Support Level
- ONL $3.75
- FULC $2.86
- Resistance Level
- ONL $3.91
- FULC $3.94
- Average True Range (ATR)
- ONL 0.15
- FULC 0.22
- MACD
- ONL 0.01
- FULC -0.00
- Stochastic Oscillator
- ONL 71.76
- FULC 10.19
About ONL Orion Office REIT Inc.
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.